• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136).
  

PubMed=20149136; DOI=10.1111/j.1755-148X.2010.00685.x; PMCID=PMC2848976
Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., Krauthammer M., McCusker J.P., Kluger Y., Sznol M.
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Pigment Cell Melanoma Res. 23:190-200(2010)

PubMed=21521745; DOI=10.1158/1541-7786.MCR-10-0512; PMCID=PMC3117976
Tworkoski K., Singhal G., Szpakowski S., Zito C.I., Bacchiocchi A., Muthusamy V., Bosenberg M.W., Krauthammer M., Halaban R., Stern D.F.
Phosphoproteomic screen identifies potential therapeutic targets in melanoma.
Mol. Cancer Res. 9:801-812(2011)

PubMed=21543894; DOI=10.4161/cc.10.11.15777; PMCID=PMC3233487
Chan E., Patel R., Nallur S., Ratner E., Bacchiocchi A., Hoyt K., Szpakowski S., Godshalk S., Ariyan S., Sznol M., Halaban R., Krauthammer M., Tuck D., Slack F.J., Weidhaas J.B.
MicroRNA signatures differentiate melanoma subtypes.
Cell Cycle 10:1845-1852(2011)